Conformis, Inc. (CFMS)

NASDAQ: CFMS · IEX Real-Time Price · USD
3.72
+0.20 (5.68%)
At close: Dec 9, 2022 4:00 PM
3.60
-0.12 (-3.23%)
After-hours: Dec 9, 2022 5:30 PM EST
5.68%
Market Cap 26.54M
Revenue (ttm) 60.05M
Net Income (ttm) -62.73M
Shares Out 7.25M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Nov 10, 2022
Volume 204,944
Open 3.54
Previous Close 3.52
Day's Range 3.53 - 4.22
52-Week Range 1.2 - 21.3
Beta 1.09
Analysts Buy
Price Target 23.97 (+544.4%)
Earnings Date Nov 2, 2022

About CFMS

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also prov... [Read more]

Industry Health Care Equipment & Supplies
IPO Date Jul 1, 2015
Employees 310
Stock Exchange NASDAQ
Ticker Symbol CFMS
Full Company Profile

Financial Performance

In 2021, Conformis's revenue was $99.86 million, an increase of 45.23% compared to the previous year's $68.76 million. Losses were -$2.41 million, -90.07% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CFMS stock is "Buy." The 12-month stock price forecast is 23.97, which is an increase of 544.35% from the latest price.

Price Target
$23.97
(544.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Conformis, Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule

BILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market (“NASDAQ...

1 week ago - GlobeNewsWire

Conformis Announces First Procedure Performed Using New Actera™ Hip System

First Actera™ procedure underscores company's ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertise First Actera™ procedure ...

1 week ago - GlobeNewsWire

Conformis Announces Full Commercial Launch of Imprint™

Conformis' Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA) Conformis' Imprint™ knee system introduces the new “Made-to-Measure” produc...

3 weeks ago - GlobeNewsWire

Conformis, Inc. Announces Settlement of Medacta Patent Litigation

Conformis Settles Medacta Litigation Related to Patient-Specific Instruments Conformis Settles Medacta Litigation Related to Patient-Specific Instruments

3 weeks ago - GlobeNewsWire

ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates

ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Conformis Reports Third Quarter 2022 Financial Results

BILLERICA, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today fina...

1 month ago - GlobeNewsWire

Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022

BILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will...

2 months ago - GlobeNewsWire

Conformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration

New design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implants New design adds in...

2 months ago - GlobeNewsWire

Conformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference

BILLERICA, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Ma...

3 months ago - GlobeNewsWire

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

ConforMIS (CFMS) delivered earnings and revenue surprises of -12.50% and 1.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Conformis Reports Second Quarter 2022 Financial Results

BILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today fina...

4 months ago - GlobeNewsWire

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

Agreement enables interested Vizient members, including academic medical centers, acute care facilities, and ambulatory surgery centers (ASCs), to purchase Conformis knee and hip replacement solutions, ...

4 months ago - GlobeNewsWire

Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

BILLERICA, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Ma...

4 months ago - GlobeNewsWire

Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will...

5 months ago - GlobeNewsWire

Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference

BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mar...

6 months ago - GlobeNewsWire

ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates

ConforMIS (CFMS) delivered earnings and revenue surprises of -28.57% and 11.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Conformis Reports First Quarter 2022 Financial Results

BILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today finan...

7 months ago - GlobeNewsWire

Conformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022

BILLERICA, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market op...

7 months ago - GlobeNewsWire

Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer.

8 months ago - GlobeNewsWire

Conformis Partners with Synchrony to Offer CareCredit Financial Services to Orthopedic Patients

The partnership, announced at the 2022 AAOS conference, will enable patients that have selected a fully personalized Conformis implant – through the company's Image-to-Implant Platinum Services Program ...

8 months ago - GlobeNewsWire

Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary.

8 months ago - GlobeNewsWire

Gary Fischetti nominated to join Conformis' Board of Directors

BILLERICA, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Gary P. Fischetti has been nominated to stand for election to the Company's Board of Directors at...

8 months ago - GlobeNewsWire

Conformis' Q4 Miss Street View As Earnings Impacted By Surge In COVID-19 Cases

Conformis Inc's (NASDAQ: CFMS) Q4 revenues decreased 8% Y/Y to $15.4 million, missing the consensus of $15.61 million. The decrease is primarily due to deferred and rescheduled elective surgeries due to...

9 months ago - Benzinga

Conformis, Inc. Reports Fourth Quarter and Year End 2021 Financial Results

BILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today fina...

9 months ago - GlobeNewsWire

Conformis, Inc. to Participate in Upcoming Investor Conferences

BILLERICA, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Ma...

9 months ago - GlobeNewsWire